Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | PER2 | O15055 | 7/20 | 0.36 |
| ▸ | CRY1 | Q16526 | 7/20 | 0.36 |
| ▸ | CRY2 | Q49AN0 | 7/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | PREP | P48147 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 3/20 | 0.33 |
| ▸ | CALCA | P06881 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8282033 | 1.00 | CTSK (0.41) | CTSKCTSLCTSBCA1CA2 | |
| SCHEMBL13622636 | 0.96 | CTSK (0.39) | CTSKCTSLCTSBCA1CA2 | |
| SCHEMBL8282004 | 0.96 | CTSK (0.39) | CTSKCTSLCTSBCA1CA2 | |
| SCHEMBL13622641 | 0.82 | CA1 (0.50) | CTSKCTSLCTSBCA1CA2 | |
| SCHEMBL8283754 | 0.82 | CA1 (0.50) | CTSKCTSLCTSBCA1CA2 | |
| SCHEMBL13622697 | 0.80 | CTSK (0.37) | CTSKCTSLCTSBCA1CA2 | |
| SCHEMBL12601000 | 0.80 | CTSK (0.37) | CTSKCTSLCTSBCA1CA2 | |
| SCHEMBL13684451 | 0.77 | PER2 (0.40) | PER2CRY1CRY2 | |
| SCHEMBL8282064 | 0.77 | CA1 (0.38) | CTSKCTSLCTSBCA1CA2 | |
| SCHEMBL13622721 | 0.77 | CA1 (0.38) | CTSKCTSLCTSBCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7619094-B2 | Ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus | SCHERING CORPORATION (US) | 2009-11-17 | — | — | US | disclosed |
| US-20070093430-A1 | Novel ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus | MERCK SHARP & DOHME CORP. | 2007-04-26 | — | — | US | disclosed |
| US-7173057-B2 | Ketoamides with cyclic P4'S as inhibitors of NS3 protease of hepatitis C virus | SCHERING CORPORATION (US) | 2007-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093430-A1 | Novel ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus | PREP, PRSS1, P4HB | CTSK 949/4885CTSL 332/4885CTSB 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.